On September 13, 2024, ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, announced that it has secured $65 million in Series D financing. The round was led by Johnson & Johnson Innovation – JJDC, Inc. and included investors Bios Partners, Novartis Venture Fund, and Visionary Ventures, among others. Wilson Sonsini Goodrich & Rosati advised ONL Therapeutics on patent matters related to the transaction.

ONL Therapeutics is the first and only clinical-stage company focused on the unique mechanism of action (MOA) preventing Fas-mediated death of retinal cells and inflammatory signaling pathways, the root causes of vision loss and blindness. The proceeds from the Series D financing will advance the development of ONL1204 Ophthalmic Solution with the initiation of a Phase 2 global study for the treatment of geographic atrophy (GA) associated with dry age-related macular degeneration (AMD).

The Wilson Sonsini team that advised ONL Therapeutics on patent matters related to the financing included Greg Mitchell, Brett Zirkle, Tess Oram, and Lou Lieto.

For more information, please see ONL Therapeutics’ news release.